| Year |
Citation |
Score |
| 2024 |
Ghazi PC, O'Toole KT, Srinivas Boggaram S, Scherzer MT, Silvis MR, Zhang Y, Bogdan M, Smith BD, Lozano G, Flynn DL, Snyder EL, Kinsey CG, McMahon M. Inhibition of ULK1/2 and KRAS controls tumor growth in preclinical models of lung cancer. Biorxiv : the Preprint Server For Biology. PMID 38370808 DOI: 10.1101/2024.02.06.579200 |
0.368 |
|
| 2023 |
Gillis K, Orellana WA, Wilson E, Parnell TJ, Fort G, Dadzie HE, Zhang X, Snyder EL. FoxA1/2-dependent epigenomic reprogramming drives lineage switching in lung adenocarcinoma. Biorxiv : the Preprint Server For Biology. PMID 37961260 DOI: 10.1101/2023.10.30.564775 |
0.305 |
|
| 2022 |
Kong R, Patel AS, Sato T, Jiang F, Yoo S, Bao L, Sinha A, Tian Y, Fridrikh M, Liu S, Feng J, He X, Jiang J, Ma Y, Grullon K, ... ... Snyder EL, et al. Transcriptional Circuitry of NKX2-1 and SOX1 Defines an Unrecognized Lineage Subtype of Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine. PMID 35848993 DOI: 10.1164/rccm.202110-2358OC |
0.372 |
|
| 2022 |
Orstad G, Fort G, Parnell TJ, Jones A, Stubben C, Lohman B, Gillis KL, Orellana W, Tariq R, Klingbeil O, Kaestner K, Vakoc CR, Spike BT, Snyder EL. FoxA1 and FoxA2 control growth and cellular identity in NKX2-1-positive lung adenocarcinoma. Developmental Cell. PMID 35835117 DOI: 10.1016/j.devcel.2022.06.017 |
0.34 |
|
| 2021 |
Ingram K, Samson SC, Zewdu R, Zitnay RG, Snyder EL, Mendoza MC. NKX2-1 controls lung cancer progression by inducing DUSP6 to dampen ERK activity. Oncogene. PMID 34689179 DOI: 10.1038/s41388-021-02076-x |
0.373 |
|
| 2021 |
Zewdu R, Mehrabad EM, Ingram K, Fang P, Gillis KL, Camolotto SA, Orstad G, Jones A, Mendoza MC, Spike BT, Snyder EL. An NKX2-1/ERK/WNT feedback loop modulates gastric identity and response to targeted therapy in lung adenocarcinoma. Elife. 10. PMID 33821796 DOI: 10.7554/eLife.66788 |
0.386 |
|
| 2020 |
Camolotto SA, Belova VK, Torre-Healy L, Vahrenkamp JM, Berrett KC, Conway H, Shea J, Stubben C, Moffitt R, Gertz J, Snyder EL. Reciprocal regulation of pancreatic ductal adenocarcinoma growth and molecular subtype by HNF4α and SIX1/4. Gut. PMID 32826305 DOI: 10.1136/Gutjnl-2020-321316 |
0.321 |
|
| 2020 |
Mollaoglu G, Jones A, Wait S, Mukhopadhyay A, Jeong S, Arya R, Camolotto S, Mosbruger T, Stubben C, Conley C, Bhutkar A, Vahrenkamp J, Berrett K, Cessna M, Lane T, ... ... Snyder E, et al. Abstract B72: Lineage specifiers SOX2 and NKX2-1 inversely regulate tumor cell fate and neutrophil recruitment in lung cancer Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm18-B72 |
0.494 |
|
| 2019 |
Kinsey CG, Camolotto SA, Boespflug AM, Gullien KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW, Cavalieri CC, ... ... Snyder EL, et al. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nature Medicine. PMID 30833748 DOI: 10.1038/S41591-019-0367-9 |
0.392 |
|
| 2019 |
Camolotto SA, Torre-Healy L, Belova V, Vahrenkamp J, Berrett K, Stubben C, Gertz J, Moffit R, Snyder EL. Abstract C38: HNF4a regulates progression and molecular subtype of pancreatic ductal adenocarcinoma Cancer Research. 79. DOI: 10.1158/1538-7445.Panca19-C38 |
0.438 |
|
| 2019 |
Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW, Cavalieri CC, ... ... Snyder EL, et al. Abstract 2183: Protective autophagy elicited by RAF®MEK®ERK inhibition suggests a treatment strategy for pancreatic cancer Cancer Research. 79: 2183-2183. DOI: 10.1158/1538-7445.Am2019-2183 |
0.391 |
|
| 2018 |
Camolotto SA, Belova VK, Snyder EL. The role of lineage specifiers in pancreatic ductal adenocarcinoma. Journal of Gastrointestinal Oncology. 9: 1005-1013. PMID 30603119 DOI: 10.21037/Jgo.2018.05.04 |
0.369 |
|
| 2018 |
Camolotto SA, Pattabiraman S, Mosbruger TL, Jones A, Belova VK, Orstad G, Streiff M, Salmond L, Stubben C, Kaestner KH, Snyder EL. FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer. Elife. 7. PMID 30475207 DOI: 10.7554/Elife.38579 |
0.464 |
|
| 2018 |
Mollaoglu G, Jones A, Wait SJ, Mukhopadhyay A, Jeong S, Arya R, Camolotto SA, Mosbruger TL, Stubben CJ, Conley CJ, Bhutkar A, Vahrenkamp JM, Berrett KC, Cessna MH, Lane TE, ... ... Snyder EL, et al. The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment. Immunity. 49: 764-779.e9. PMID 30332632 DOI: 10.1016/J.Immuni.2018.09.020 |
0.472 |
|
| 2018 |
Caswell DR, Chuang CH, Ma RK, Winters IP, Snyder EL, Winslow MM. Tumor Suppressor Activity of Selenbp1, a Direct Nkx2-1 Target, in Lung Adenocarcinoma. Molecular Cancer Research : McR. PMID 30002193 DOI: 10.1158/1541-7786.Mcr-18-0392 |
0.439 |
|
| 2018 |
Camolotto SA, Pattabiraman S, Mosbruger TL, Jones A, Belova VK, Orstad G, Streiff M, Salmond L, Stubben C, Kaestner KH, Snyder EL. Author response: FoxA1 and FoxA2 drive gastric differentiation and suppress squamous identity in NKX2-1-negative lung cancer Elife. DOI: 10.7554/Elife.38579.027 |
0.361 |
|
| 2018 |
Mollaoglu G, Jones A, Mukhopadhyay A, Gertz J, Jones K, Snyder E, Oliver TG. Abstract PR05: Lineage specifiers SOX2 and NKX2-1 inversely regulate lung tumor immune microenvironment Cancer Research. 78. DOI: 10.1158/1538-7445.Mousemodels17-Pr05 |
0.46 |
|
| 2015 |
Li CM, Gocheva V, Oudin MJ, Bhutkar A, Wang SY, Date SR, Ng SR, Whittaker CA, Bronson RT, Snyder EL, Gertler FB, Jacks T. Foxa2 and Cdx2 cooperate with Nkx2-1 to inhibit lung adenocarcinoma metastasis. Genes & Development. 29: 1850-62. PMID 26341558 DOI: 10.1101/Gad.267393.115 |
0.473 |
|
| 2014 |
Zhang YX, Sicinska E, Czaplinski JT, Remillard SP, Moss S, Wang Y, Brain C, Loo A, Snyder EL, Demetri GD, Kim S, Kung AL, Wagner AJ. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. Molecular Cancer Therapeutics. 13: 2184-93. PMID 25028469 DOI: 10.1158/1535-7163.Mct-14-0387 |
0.412 |
|
| 2014 |
Sioletic S, Czaplinski J, Hu L, Fletcher JA, Fletcher CD, Wagner AJ, Loda M, Demetri GD, Sicinska ET, Snyder EL. c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas. The Journal of Pathology. 234: 190-202. PMID 24852265 DOI: 10.1002/Path.4379 |
0.343 |
|
| 2013 |
Guo JY, Karsli-Uzunbas G, Mathew R, Aisner SC, Kamphorst JJ, Strohecker AM, Chen G, Price S, Lu W, Teng X, Snyder E, Santanam U, Dipaola RS, Jacks T, Rabinowitz JD, et al. Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes & Development. 27: 1447-61. PMID 23824538 DOI: 10.1101/Gad.219642.113 |
0.401 |
|
| 2013 |
Snyder EL, Watanabe H, Magendantz M, Hoersch S, Chen TA, Wang DG, Crowley D, Whittaker CA, Meyerson M, Kimura S, Jacks T. Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Molecular Cell. 50: 185-99. PMID 23523371 DOI: 10.1016/J.Molcel.2013.02.018 |
0.431 |
|
| 2013 |
Watanabe H, Francis JM, Woo MS, Etemad B, Lin W, Fries DF, Peng S, Snyder EL, Tata PR, Izzo F, Schinzel AC, Cho J, Hammerman PS, Verhaak RG, Hahn WC, et al. Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Genes & Development. 27: 197-210. PMID 23322301 DOI: 10.1101/Gad.203208.112 |
0.418 |
|
| 2013 |
Watanabe H, Francis JM, Woo MS, Etemad B, Lin W, Fries DF, Peng S, Snyder EL, Tata PR, Schinzel AC, Cho J, Hammerman PS, Verhaak RG, Hahn WC, Rajagopal J, et al. Abstract 3127: Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. Cancer Research. 73: 3127-3127. DOI: 10.1158/1538-7445.Am2013-3127 |
0.443 |
|
| 2012 |
Farago AF, Snyder EL, Jacks T. SnapShot: Lung cancer models. Cell. 149: 246-246.e1. PMID 22464334 DOI: 10.1016/J.Cell.2012.03.015 |
0.34 |
|
| 2012 |
Sioletic S, Sicinska E, Loda M, Fletcher CDM, Fletcher JA, Demetri GD, Snyder EL. Abstract LB-270: Genomic amplification of c-Jun activates genes that promote proliferation and cell migration in liposarcoma Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-270 |
0.389 |
|
| 2011 |
Gutierrez A, Snyder EL, Marino-Enriquez A, Zhang YX, Sioletic S, Kozakewich E, Grebliunaite R, Ou WB, Sicinska E, Raut CP, Demetri GD, Perez-Atayde AR, Wagner AJ, Fletcher JA, Fletcher CD, et al. Aberrant AKT activation drives well-differentiated liposarcoma. Proceedings of the National Academy of Sciences of the United States of America. 108: 16386-91. PMID 21930930 DOI: 10.1073/Pnas.1106127108 |
0.404 |
|
| 2011 |
Dooley AL, Winslow MM, Chiang DY, Banerji S, Stransky N, Dayton TL, Snyder EL, Senna S, Whittaker CA, Bronson RT, Crowley D, Barretina J, Garraway L, Meyerson M, Jacks T. Nuclear factor I/B is an oncogene in small cell lung cancer. Genes & Development. 25: 1470-5. PMID 21764851 DOI: 10.1101/Gad.2046711 |
0.456 |
|
| 2011 |
Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, Hubbard DD, DuPage MJ, Whittaker CA, Hoersch S, Yoon S, Crowley D, Bronson RT, Chiang DY, Meyerson M, et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature. 473: 101-4. PMID 21471965 DOI: 10.1038/Nature09881 |
0.453 |
|
| 2010 |
Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D, Snyder E, Faversani A, Coggi G, Flavin R, Bosari S, Loda M. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proceedings of the National Academy of Sciences of the United States of America. 107: 8352-6. PMID 20404174 DOI: 10.1073/Pnas.0907676107 |
0.397 |
|
| 2009 |
Gidekel Friedlander SY, Chu GC, Snyder EL, Girnius N, Dibelius G, Crowley D, Vasile E, DePinho RA, Jacks T. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell. 16: 379-89. PMID 19878870 DOI: 10.1016/J.Ccr.2009.09.027 |
0.373 |
|
| 2009 |
Snyder EL, Bailey D, Shipitsin M, Polyak K, Loda M. Identification of CD44v6(+)/CD24- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies. Laboratory Investigation; a Journal of Technical Methods and Pathology. 89: 857-66. PMID 19488035 DOI: 10.1038/Labinvest.2009.54 |
0.31 |
|
| 2009 |
Snyder EL, Sandstrom DJ, Law K, Fiore C, Sicinska E, Brito J, Bailey D, Fletcher JA, Loda M, Rodig SJ, Dal Cin P, Fletcher CD. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. The Journal of Pathology. 218: 292-300. PMID 19449367 DOI: 10.1002/Path.2564 |
0.314 |
|
| 2009 |
Winslow MM, Dayton TL, Snyder EL, Chiang DY, Kim C, Verhaak R, Crowley D, Bronson RT, Meyerson M, Jacks TE. Abstract B39: Nkx2-1 down-regulation underlies lung adenocarcinoma progression towards malignancy Cancer Research. 69. DOI: 10.1158/0008-5472.Fbcr09-B39 |
0.357 |
|
| 2008 |
Bloushtain-Qimron N, Yao J, Snyder EL, Shipitsin M, Campbell LL, Mani SA, Hu M, Chen H, Ustyansky V, Antosiewicz JE, Argani P, Halushka MK, Thomson JA, Pharoah P, Porgador A, et al. Cell type-specific DNA methylation patterns in the human breast. Proceedings of the National Academy of Sciences of the United States of America. 105: 14076-81. PMID 18780791 DOI: 10.1073/Pnas.0805206105 |
0.377 |
|
| 2005 |
Snyder EL, Saenz CC, Denicourt C, Meade BR, Cui XS, Kaplan IM, Dowdy SF. Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides. Cancer Research. 65: 10646-50. PMID 16322205 DOI: 10.1158/0008-5472.Can-05-0118 |
0.387 |
|
| 2005 |
Snyder EL, Dowdy SF. Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids in vivo. Expert Opinion On Drug Delivery. 2: 43-51. PMID 16296734 DOI: 10.1517/17425247.2.1.43 |
0.316 |
|
| 2004 |
Snyder EL, Dowdy SF. Cell penetrating peptides in drug delivery. Pharmaceutical Research. 21: 389-93. PMID 15070086 DOI: 10.1023/B:Pham.0000019289.61978.F5 |
0.318 |
|
| 2004 |
Snyder EL, Meade BR, Saenz CC, Dowdy SF. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. Plos Biology. 2: E36. PMID 14966535 DOI: 10.1371/Journal.Pbio.0020036 |
0.44 |
|
| 2003 |
Yu BD, Becker-Hapak M, Snyder EL, Vooijs M, Denicourt C, Dowdy SF. Distinct and nonoverlapping roles for pRB and cyclin D:cyclin-dependent kinases 4/6 activity in melanocyte survival. Proceedings of the National Academy of Sciences of the United States of America. 100: 14881-6. PMID 14630948 DOI: 10.1073/Pnas.2431391100 |
0.365 |
|
| 2003 |
Snyder EL, Meade BR, Dowdy SF. Anti-cancer protein transduction strategies: reconstitution of p27 tumor suppressor function. Journal of Controlled Release : Official Journal of the Controlled Release Society. 91: 45-51. PMID 12932636 DOI: 10.1016/S0168-3659(03)00212-8 |
0.404 |
|
| 2001 |
Wang T, Kobayashi T, Takimoto R, Denes AE, Snyder EL, el-Deiry WS, Brachmann RK. hADA3 is required for p53 activity. The Embo Journal. 20: 6404-13. PMID 11707411 DOI: 10.1093/Emboj/20.22.6404 |
0.334 |
|
| 1998 |
Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, Becker-Hapak M, Ezhevsky SA, Dowdy SF. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nature Medicine. 4: 1449-52. PMID 9846587 DOI: 10.1038/4042 |
0.34 |
|
| 1998 |
Inoue H, Ishii H, Alder H, Snyder E, Druck T, Huebner K, Croce CM. Sequence of the FRA3B common fragile region: implications for the mechanism of FHIT deletion. Proceedings of the National Academy of Sciences of the United States of America. 94: 14584-9. PMID 9405656 DOI: 10.1073/Pnas.94.26.14584 |
0.318 |
|
| Show low-probability matches. |